News articles about Magellan Health (NASDAQ:MGLN) have been trending somewhat positive recently, according to Accern. The research firm identifies positive and negative press coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Magellan Health earned a media sentiment score of 0.16 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 45.6529028894783 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Here are some of the news stories that may have impacted Accern Sentiment’s rankings:

Magellan Health (MGLN) traded up $0.45 on Tuesday, hitting $95.70. The stock had a trading volume of 173,921 shares, compared to its average volume of 143,662. Magellan Health has a 12 month low of $64.05 and a 12 month high of $95.90. The company has a quick ratio of 2.21, a current ratio of 2.28 and a debt-to-equity ratio of 0.62. The company has a market capitalization of $2,146.98, a PE ratio of 20.34, a price-to-earnings-growth ratio of 1.15 and a beta of 0.54.

Magellan Health (NASDAQ:MGLN) last posted its quarterly earnings data on Wednesday, November 1st. The company reported $1.64 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.24. Magellan Health had a return on equity of 9.20% and a net margin of 1.68%. The company had revenue of $1.42 billion during the quarter, compared to analysts’ expectations of $1.49 billion. During the same period in the prior year, the business earned $1.39 earnings per share. Magellan Health’s revenue for the quarter was up 9.9% compared to the same quarter last year. equities research analysts anticipate that Magellan Health will post 5.19 EPS for the current fiscal year.

MGLN has been the topic of several analyst reports. Jefferies Group reiterated a “buy” rating and set a $94.00 price target on shares of Magellan Health in a report on Friday, October 13th. BidaskClub upgraded Magellan Health from a “sell” rating to a “hold” rating in a report on Tuesday, August 8th. KeyCorp set a $105.00 price objective on Magellan Health and gave the company a “buy” rating in a research report on Friday. Raymond James Financial reissued a “hold” rating on shares of Magellan Health in a research report on Saturday. Finally, Zacks Investment Research cut Magellan Health from a “buy” rating to a “hold” rating in a research report on Wednesday, October 4th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $90.50.

In other news, insider Clapper Caskie Lewis sold 59,313 shares of the stock in a transaction that occurred on Monday, December 4th. The stock was sold at an average price of $93.99, for a total value of $5,574,828.87. Following the completion of the sale, the insider now directly owns 48,474 shares of the company’s stock, valued at $4,556,071.26. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Mostafa Kamal sold 604 shares of the stock in a transaction that occurred on Wednesday, September 13th. The shares were sold at an average price of $83.00, for a total value of $50,132.00. Following the completion of the sale, the chief executive officer now directly owns 19 shares of the company’s stock, valued at $1,577. The disclosure for this sale can be found here. Insiders sold 312,647 shares of company stock valued at $27,277,101 over the last three months. 5.00% of the stock is owned by company insiders.

COPYRIGHT VIOLATION WARNING: This story was first posted by Watch List News and is the property of of Watch List News. If you are reading this story on another site, it was illegally copied and reposted in violation of United States and international trademark & copyright legislation. The original version of this story can be accessed at

About Magellan Health

Magellan Health, Inc is engaged in the healthcare management business. The Company’s segments include Healthcare, Pharmacy Management and Corporate. It is focused on managing special populations, complete pharmacy benefits and other specialty areas of healthcare. Its Healthcare includes its management of behavioral healthcare services and employee assistance program (EAP) services, management of other specialty areas, including diagnostic imaging and musculoskeletal management, and the integrated management of physical, behavioral and pharmaceutical healthcare for special populations, delivered through Magellan Complete Care (MCC).

Insider Buying and Selling by Quarter for Magellan Health (NASDAQ:MGLN)

Receive News & Ratings for Magellan Health Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Magellan Health Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.